Last reviewed · How we verify
NCT04128046
The Effect of Platelet-rich Fibrin Matrix on Skin Rejuvenation
NA trial testing PRFM injection in Skin Rejuvenation in 30 participants. Completed in 1 June 2019.
28 May 2019
Quick facts
| Lead sponsor | New York Medical College |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 3 September 2018 |
| Primary completion | 28 May 2019 |
| Estimated completion | 1 June 2019 |
| Sites | 1 location across United States |
Drugs / interventions tested
- PRFM injection
- Saline injection
Conditions studied
- Skin Rejuvenation — all drugs for Skin Rejuvenation →
- Skin Quality — all drugs for Skin Quality →
- Wrinkle — all drugs for Wrinkle →
- Nasolabial Fold — all drugs for Nasolabial Fold →
Sponsor
New York Medical College
Who can join
18 and older, any sex, with Skin Rejuvenation or Skin Quality. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Platelet-rich fibrin matrix (PRFM) is made from platelets that are extracted from a patient's blood, and many plastic surgeons and dermatologists have used it to fill in wrinkles and lines on the face. Both patients and doctors have observed that it gives extra volume in these areas and improves overall appearance. However, there is no research that shows how PRFM affects skin quality, such as pores, spots, red areas, and texture. The aim of this study is to determine whether PRFM has a role in rejuvenating facial skin.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04128046
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Skin Rejuvenation
Currently open trials in the same condition.
- NCT07467954 — Comparative Effectiveness of Long-Pulsed 1064-nm Nd:YAG and Fractional CO₂ Laser in Skin Rejuvenation · NA · recruiting
- NCT07160777 — Performance and Safety of Semical Dermal Fillers in Facial Rejuvenation · active not recruiting
Other New York Medical College trials
Trials by the same sponsor.
- NCT06617286 — CD30 CAR T-cells Post AutoHSCT for Poor-risk Hodgkin Lymphoma · Phase 1, PHASE2 · not yet recruiting
- NCT07225972 — Phase 3 Randomized Trial for Refractory ADV or CMV Infection With Family Matched CTLs and Standard of Care (SOC) vs SOC · Phase 3 · not yet recruiting
- NCT07013565 — Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL · Phase 2 · active not recruiting
- NCT05987124 — Defibrotide Dose-escalation for SOS Post-HSCT · Phase 2 · recruiting
- NCT05564598 — CMV CTLs in Neonates With CMV Infection · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04128046 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by New York Medical College
- Last refreshed: 22 October 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04128046.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing